Telehealth Platform Teladoc Health is expanding its collaboration with Microsoft to integrate the tech giant’s AI solutions into its platform, allowing providers to automate the creation of clinical documentation during virtual exams.
The virtual care company will integrate Microsoft Azure OpenAI Service, Azure Cognitive Services and conversational and ambient clinical documentation solution Nuance Dragon Ambient Experience (DAX) in Teladoc Health Solo. Solo is an enterprise platform that can be integrated with existing IT systems to deliver virtual care.
Teladoc Health Medical Group will also use Nuance DAX Express for its Teladoc Healthcare visits. DAX Express is an AI-enabled clinical documentation application that will combine Nuance’s capabilities with OpenAI’s GPT4 on Azure OpenAI Service, allowing coordinated care by transferring documentation to other clinicians.
of Shares of the virtual care company rose amid news of the expanded partnership.
“Administrative burden and staff shortages are the main reasons why doctors are leaving the profession,” said Dr. Vidya Raman-Tangella, chief medical officer at Teladoc Health. “We’re focused on using AI to reaffirm and build the doctor-patient relationship at a time when technology often does the opposite. We’re proud to partner with Microsoft and Nuance to break new ground.”
THE BIGGEST TREND
In 2021, Teladoc and Microsoft announced their partnership to improve telehealth technology and administrative processes by offering Solo in the Microsoft Teams environment for health systems and hospitals.
In the same year, Microsoft acquired conversational AI and clinical ambient intelligence platform Nuance in an all-cash transaction worth $19.7 billion.
In March, Microsoft’s Nuance Communications announced its clinical documentation tool, Dragon Ambient eXperience Express, which used the latest version of OpenAI’s artificial intelligence language model, GPT-4, launched earlier this year. Nuance’s tool builds on the company’s DAX documentation product, launched in 2020.
Last week, a federal judge dismissed a securities class action lawsuit filed in 2022 against Teladoc Health from shareholder Jeremy Schneider on behalf of parties that purchased Teladoc shares between February 2021 and July 2022.
The suit belonged to the virtual care company $18.5 billion merger with chronic care platform Livongo, alleging that its representatives misled investors by downplaying the challenges it faced integrating Livongo. He also alleged that the company made misleading statements and “artificially inflated Teladoc’s stock price” during those 17 months.
